Parkisnon 증후군에 있어서의 Bromocriptine의 치료효과에 관한 연구

Abstract

Therapeutic eκects of bromocriptine were evaluated in 16 idiopathic Parkinsonism patients. 22.5mg of bromocriptine was added to the conventional antiparkinsonian agents including L-dopa, and clinical evaluation was performed according to the Northwestern University Disability Scales(NUDS) & Physical Eximination Disability Scales(PEDS). Both NUDS and PEDS showed a significant improvement in score after bromocriptine therapy, especially in walking, speech, tremor and finger dexterity. The eight responders had taken significantly larger doses of L-dopa and shorter periods of L-dopa treatment than non-responders. Bromocriptine showed a therapeutic effect as an adjuvant to the L-dopa in idiopathic Parkinsonism.